Title : TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.

Pub. Date : 2021 Dec

PMID : 34779146






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Impaired EPR in TP53-mutated breast cancer cases was independent from the Oncotype DX Recurrence Score group and was seen both with tamoxifen- and aromatase inhibitor-based pET (p = 0.0005 each). Tamoxifen tumor protein p53 Homo sapiens